ArticleACS nano2019
Orally Administrable Therapeutic Synthetic Nanoparticle for Zika Virus.
Article in ACS nano, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.The Journal of antibiotics · 2020Pooled it
- Analytical Validation of an HPLC-DAD Method for Ivermectin Quantification in Polymeric Nanocapsules.ACS omega · 2026Article
- Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery.Chemical biology & drug design · 2026Review
- Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines · 2025Review
- Ivermectin Inhibits Zika Virus Replication in Vitro But Does Not Prevent Zika Virus Infection in Rhesus Macaques (Macaca mulatta).The American journal of tropical medicine and hygiene · 2025Article
- Ivermectin-Loaded Mesoporous Silica and Polymeric Nanocapsules: Impact on Drug Loading, In Vitro Solubility Enhancement, and Release Performance.Pharmaceutics · 2024Article
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.Materials today. Chemistry · 2023Review
- Antiviral role of nanomaterials: a material scientist's perspective.RSC advances · 2022Review
- Biomaterial-targeted precision nanoparticle delivery to the injured spinal cord.Acta biomaterialia · 2022Article
- An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19.Journal of nanobiotechnology · 2022Review
- Sparking Nano-Metals on a Surface of Polyethylene Terephthalate and Its Application: Anti-Coronavirus and Anti-Fogging Properties.International journal of molecular sciences · 2022Article
- COVID-19: Consequences on pregnant women and neonates.Health sciences review (Oxford, England) · 2022Review
- Transformation of Amphiphilic Antiviral Drugs into New Dimensional Nanovesicles Structures.ACS omega · 2022Article
- Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties.International journal of pharmaceutics · 2022Article
- Intersection of Inorganic Chemistry and Nanotechnology for the Creation of New Cancer Therapies.Accounts of materials research · 2022Article
- Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium.Bioactive materials · 2022Article
- Nanoparticle approaches against SARS-CoV-2 infection.Current opinion in solid state & materials science · 2021Article
- COVID-19 and Ivermectin: Potential threats associated with human use.Journal of molecular structure · 2021Article
- Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The spread of Zika virus (ZIKV) infection across the USA and various countries in the last three years will not only have a direct impact on the U.S. health care system but has caused international concerns as well. The ultimate impact of ZIKV infection remains to be understood. Currently, there are no therapeutic or vaccine options available to protect those infected by ZIKV. The drug ivermectin (IVM) was found to be a viable agent for the prevention of transmission of ZIKV. Ivermectin is unstable in the presence of water and does not remain in adequate concentration in the human bloodstream to be effective in treatment for ZIKV. Biodegradable nanoparticles would aid in the delivery of ivermectin by providing a high enough concentration of drug and ensuring the drug is gradually released to maintain an appropriate level in the body. The overall goal of this study was to develop and optimize an orally administrable nanoformulation of IVM which can circulate in the blood for a long period for efficient delivery. To achieve the goal, we synthesized and optimized a synthetic nanoformulation of IVM for oral use which can cross the intestinal epithelial barrier to enter the bloodstream. Our studies documented that when delivered with the synthetic nanoparticle (NP), IVM can be accumulated in the blood at a higher concentration and preliminary studies highlighted that NP delivered IVM has the ability to target nonstructural 1 protein of ZIKV. For potential clinical relevance, long-term storable formulation of IVM-nanoparticle in dry powder state for inclusion in a capsule form and cryoprotectant containing frozen forms revealed promising findings. Further, our preliminary
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.